Clinical Studies
Recent submissions
-
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer
(WILEY, 2024-06-01)<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Elevated circulating growth differentiation factor (GDF15/MIC‐1), interleukin 4 (IL4), and IL6 levels were associated with resistance ... -
Best Overall Response-Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE.
(AMER ASSOC CANCER RESEARCH, 2024-06-03)PURPOSE: This exploratory analysis evaluated the tumor samples of the patients treated with doxorubicin (with or without olaratumab) in a negative phase III ANNOUNCE trial to better understand the complexity of advanced ... -
Herding clonal evolution to overcome drug resistance in high-grade serous ovarian cancer
(Institute of Cancer Research (University Of London), 2024-06-04)Ovarian cancer (OC) is one of the most common malignancies responsible for cancer-related deaths in women, and finding new treatment strategies is an area of unmet clinical need. To investigate how the concepts of cancer ... -
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.
(ELSEVIER, 2024-03-01)The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as ... -
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
(Elsevier BV, 2024-03-01)For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an ... -
Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
(American Society of Clinical Oncology (ASCO), 2024-03-01)PURPOSE: Accurate understanding of the genomic and transcriptomic data provided by next-generation sequencing (NGS) is essential for the effective utilization of precision oncology. Molecular tumor boards (MTBs) aim to ... -
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
(ELSEVIER, 2024-03-01)In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the ... -
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.
(ELSEVIER, 2024-03-01)The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently ... -
Exploring mechanisms of response and resistance to immuno-oncology approaches in melanoma
(Institute of Cancer Research (University Of London), 2024-05-21)Background Immuno-oncology strategies have transformed the prognosis of advanced melanoma; in particular, immune checkpoint inhibitors (ICIs) provide durable response in a subset of patients, while tebentafusp (tebe) is ... -
Targeting the inflammatory response in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2024-05-20)Prostate cancer is a leading cause of male cancer mortality. Despite inflammation being implicated in prostate cancer initiation and progression, patient outcomes have been minimally impacted by immunotherapies that have ... -
"Why am I still suffering?": Experience of long-term fatigue and neurocognitive changes in oropharyngeal cancer survivors following (chemo)radiotherapy.
(Elsevier BV, 2024-06-01)BACKGROUND: Late effects of cancer treatment, such as neurocognitive deficits and fatigue, can be debilitating. Other than head and neck-specific functional deficits such as impairments in swallowing and speech, little is ... -
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
(AMER ASSOC CANCER RESEARCH, 2024-05-15)PURPOSE: Tuvusertib (M1774) is a potent, selective, orally administered ataxia telangiectasia and Rad3-related (ATR) protein kinase inhibitor. This first-in-human study (NCT04170153) evaluated safety, tolerability, maximum ... -
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
(ELSEVIER, 2024-04-01)BACKGROUND: Retifanlimab is a humanized, hinge-stabilized immunoglobulin G4κ monoclonal antibody against human programmed cell death protein 1 (PD-1). This first-in-human, phase I study assessed the safety and efficacy of ... -
Chronic airflow obstruction attributable to poverty in the multinational Burden of Obstructive Lung Disease (BOLD) study.
(BMJ PUBLISHING GROUP, 2023-09-01)Poverty is strongly associated with all-cause and chronic obstructive pulmonary disease (COPD) mortality. Less is known about the contribution of poverty to spirometrically defined chronic airflow obstruction (CAO)-a key ... -
Adult brain tumour research in 2024: Status, challenges and recommendations.
(WILEY, 2024-04-01)In 2015, a groundswell of brain tumour patient, carer and charity activism compelled the UK Minister for Life Sciences to form a brain tumour research task and finish group. This resulted, in 2018, with the UK government ... -
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials.
(ELSEVIER SCIENCE INC, 2024-03-26)BACKGROUND: Better use of healthcare systems data, collected as part of interactions between patients and the healthcare system, could transform planning and conduct of randomised controlled trials. Multiple challenges to ... -
Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives.
(BMJ, 2024-03-19)OBJECTIVES: To explore the importance of, and barriers to achieving, diversity in early-phase clinical trials. DESIGN: Qualitative interviews analysed using thematic analysis. SETTING AND PARTICIPANTS: Five professionals ... -
Molecular subtypes of cancer-associated fibroblasts and their regulation of the tumour microenvironment in pancreatic ductal adenocarcinoma.
(Institute of Cancer Research (University Of London), 2024-03-21)Pancreatic Ductal Adenocarcinoma (PDAC) remains a leading cause of cancer-related deaths, with a 5-year survival rate of less than 10 % in Western countries. Transcriptomic analysis of PDAC in the last decade has unearthed ... -
Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes
(Springer Science and Business Media LLC, 2024-02-15)<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>The presence of germline mutations plays an increasingly important role in risk assessment and treatment ...